Are women with vaginismus more susceptible to developing bipolar disorder? This study investigated the affective temperaments of women with vaginismus compared to healthy controls. The results may surprise you.
As you probably know, sexual dysfunction is a common side effect of antidepressants and antipsychotics. This secondary analysis of an RCT examines whether the atypical antipsychotic lurasidone was linked to emergence of sexual dysfunction in a group of patients with MDD and mixed features. Read the article to see if an association was found.
Oseltamivir (Tamiflu) is widely used for the treatment of influenza. However, adverse neuropsychiatric effects, including behavioral changes and perceptional disturbance, have been observed in oseltamivir-treated patients. Here, read about a patient who exhibited an increased libido and irregular behavior after treatment with oseltamivir. Could an increase in dopamine levels partially explain these behavioral changes?
Although mood disorders are not uncommon in patients with paraphilias, subthreshold presentations, especially cyclothymia, are often missed. This is a report of voyeurism in a young man with an underlying cyclothymic disorder who was successfully managed with sodium valproate coupled with psychotherapy.
A variety of pharmacologic interventions have been utilized to manage behavioral and psychological symptoms of dementia. Is nabilone an effective treatment option for agitation and sexual disinhibition, which are particularly problematic to treat?
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”